TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) [Seeking Alpha]
TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.
TG Therapeutics (NASDAQ:TGTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones [Yahoo! Finance]
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones